LAS VEGAS, March 26, 2007 (PRIME NEWSWIRE) -- Samaritan Pharmaceuticals Inc. (AMEX:LIV) a developer of innovative drugs, announced today it was featured in the eighteenth edition 2007 of Zillion Business Review. In an interview with Samaritan's Investor Relations Specialist, Richard Brown, the article highlighted the company's Alzheimer's drug candidate SP-233. Zillion is a business magazine for international enterprises and is published in the Netherlands. To read the article in its entirety, go to the following web link:
http://www.samaritanpharma.com/news_03-23-07_Zillion_magazine_article.asp
Samaritan Pharmaceuticals: "We LIV....to Save Lives."
Samaritan is a small-cap Biotech, driven to discover, develop and commercialize innovative therapeutics' for AIDS, Alzheimer's, Cancer and Heart disease patients. Look at www.samaritanpharma.com. Please register on Website so we can notify you of upcoming conference calls, news and events.
Click here: Samaritan Pharmaceuticals -- Samaritan Technology Videos: http://www.samaritanpharma.com/html/videos.html
Disclaimer
The company disclaims any information that is created by an outside party and endorses only information that is communicated by its press releases, filings and Website. This news release contains forward-looking statements that reflect management's current beliefs about the potential for its drug candidates, science and technology. However, as with any biopharmaceutical under development, there are significant risks and uncertainties in the process of development and regulatory review. There are no guarantees that products will prove to be commercially successful. For additional information about the factors that affect the company's business, please read the company's latest Form 10-K/A filed November 2, 2006. The company undertakes no duty to update forward-looking statements.
The Samaritan Pharmaceuticals Inc. logo is available at http://www.primezone.com/newsroom/prs/?pkgid=2670